GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Short Interest

Abionyx Pharma (XPAR:ABNX) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Abionyx Pharma's Short Interest

For the Biotechnology subindustry, Abionyx Pharma's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abionyx Pharma's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abionyx Pharma's Short Interest distribution charts can be found below:

* The bar in red indicates where Abionyx Pharma's Short Interest falls into.


Abionyx Pharma (XPAR:ABNX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Short Interest
Comparable Companies
XPAR:ALACT XPAR:ALGEN XPAR:GNRO XPAR:ALCLS XPAR:PHXM XPAR:ALVIO XPAR:ALDVI XPAR:SIGHT XPAR:ALCOX XPAR:POXEL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
609:Germany
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Website
https://www.abionyx.com
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines